Log in to your Inderes Free account to see all free content on this page.
Novonesis
354.30 DKK
+1.66 %
Less than 1K followers
NSIS B
NASDAQ Copenhagen
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Valuation
Income statement
Income statement
Financial statements, revenue, EBIT, valuation metrics, and quarterly estimates for Novonesis
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Revenue | 14,374.0 | 14,012.0 | 14,951.0 | 17,553.0 | 17,899.0 | 28,589.4 | 31,050.2 |
| growth-% | -2.5 % | 6.7 % | 17.4 % | 2.0 % | 59.7 % | 8.6 % | |
| EBITDA | 5,221.0 | 4,918.0 | 5,423.0 | 6,046.0 | 5,365.0 | 9,659.3 | 11,525.8 |
| EBIT | 4,039.0 | 3,652.0 | 4,007.0 | 4,561.0 | 3,976.0 | 3,736.4 | 6,099.4 |
| Profit before taxes | 3,799.0 | 3,521.0 | 3,924.0 | 4,556.0 | 3,909.0 | 3,110.6 | 5,600.5 |
| Net income | 3,155.0 | 2,826.0 | 3,145.0 | 3,686.0 | 3,039.0 | 2,280.6 | 4,358.5 |
| EPS | 10.97 | 10.02 | 11.32 | 13.29 | 10.92 | 5.00 | 9.34 |
| Dividend | 5.25 | 5.25 | 5.50 | 6.00 | 6.20 | 4.18 | 4.25 |
| Dividend ratio | 47.9 % | 52.4 % | 48.6 % | 45.1 % | 56.8 % | 83.6 % | 45.5 % |
Login required
This content is only available for logged in users
Profitability and return on capital
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| EBITDA-% | 36.3 % | 35.1 % | 36.3 % | 34.4 % | 30.0 % | 33.8 % | 37.1 % |
| EBIT-% | 28.1 % | 26.1 % | 26.8 % | 26.0 % | 22.2 % | 13.1 % | 19.6 % |
| ROE | 27.5 % | 25.1 % | 25.8 % | 25.9 % | 21.2 % | 2.7 % | 5.4 % |
| ROI | 15.4 % | 13.8 % | 12.7 % | 13.2 % | 10.7 % | 2.0 % | 3.6 % |
Login required
This content is only available for logged in users